

RÃ¼diger Hehlmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3883492/publications.pdf>

Version: 2024-02-01

18
papers

3,397
citations

758635

12
h-index

887659

17
g-index

19
all docs

19
docs citations

19
times ranked

3406
citing authors

#	ARTICLE	IF	CITATIONS
1	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
2	Chronic myeloid leukaemia. <i>Lancet</i> , The, 2007, 370, 342-350.	6.3	423
3	Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. <i>Journal of Clinical Oncology</i> , 2014, 32, 415-423.	0.8	271
4	Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. <i>Blood</i> , 2011, 118, 6760-6768.	0.6	254
5	How I treat CML blast crisis. <i>Blood</i> , 2012, 120, 737-747.	0.6	215
6	Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. <i>Blood</i> , 2010, 115, 1880-1885.	0.6	198
7	Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. <i>Annals of Hematology</i> , 2015, 94, 2015-2024.	0.8	67
8	High-risk additional chromosomal abnormalities at low blast counts herald death by CML. <i>Leukemia</i> , 2020, 34, 2074-2086.	3.3	50
9	Chronic Myeloid Leukemia in 2020. <i>HemaSphere</i> , 2020, 4, e468.	1.2	40
10	First-line treatment selection and early monitoring patterns in chronic phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. <i>American Journal of Hematology</i> , 2017, 92, 1214-1223.	2.0	36
11	Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. <i>American Journal of Hematology</i> , 2019, 94, 46-54.	2.0	32
12	The New ELN Recommendations for Treating CML. <i>Journal of Clinical Medicine</i> , 2020, 9, 3671.	1.0	30
13	Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic phase CML in clinical practice: 3-year European SIMPLICITY data. <i>European Journal of Haematology</i> , 2021, 106, 82-89.	1.1	14
14	Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 468-479.	1.8	10
15	Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 468-479.	1.8	8
16	Prognostic relevance of CCAs/Ph ⁺ in CML settled. <i>Blood</i> , 2017, 130, 2046-2047.	0.6	2
17	What is the right dosage of dasatinib for treating chronic myeloid leukaemia?. <i>British Journal of Haematology</i> , 2021, 194, 234-234.	1.2	0
18	CML End Phase and Blast Crisis: Implications and Management. <i>Hematologic Malignancies</i> , 2021, , 179-196.	0.2	0